How to Create a COVID-19 Vaccine
Alan Joslyn Ph.D. president and CEO of UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the... Read More
Oragenics Inc. and Aragen Bioscience Enter Agreement to Accelerate Development of TerraCoV2, a COVID 19 Vaccine Candidate
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
After Acquisition, Tampa Biotech Firm Looks Toward COVID-19 Vaccine
Serendipity is the word Alan Joslyn uses to describe the meeting and eventual acquisition of a Gainesville-based biotech firm. “It’s not every... Read More
Oragenics Acquires Noachis Terra Inc., to Develop Its TerraCoV2 NIH-Generated SARS-CoV-2 (COVID 19) Vaccine Candidate Utilizing “Spike Protein”
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics Working on Treatment for Oral Mucositis With Promising AG013 Product
Alan Joslyn, CEO of UF startup and UF Innovate | Sid Martin Biotech alum Oragenics, Inc., a Tampa-based company leader in the... Read More
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of novel antibiotics against... Read More
Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
UF startup Oragenics, Inc., a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, announced... Read More
